Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02128126
Other study ID # ISA-HPV-01-12
Secondary ID 2013-001804-12
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2013
Est. completion date August 2018

Study information

Verified date March 2019
Source ISA Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety, tolerability and the HPV-specific immune responses of different doses of ISA101 vaccine with or without pegylated IFNα as combination therapy with carboplatin and paclitaxel.

To qualitatively assess the safety profile and the HPV-specific immune responses of ISA101b vaccine compared to ISA101 at the same dose levels.

To assess the safety and the HPV-specific immune responses of ISA101b vaccine with carboplatin, paclitaxel with or without bevacizumab.


Description:

A majority of cervical carcinomas are caused by an uncontrolled, persistent infection with high risk Human Papilloma Virus (HPV). ISA101/ISA101b is a novel therapeutic synthetic long peptide (SLP) vaccine targeting HPV16 which is being developed and has shown efficacy in patients with high-grade premalignant vulvar lesions caused by HPV with only minor toxicity. For most advanced cancers, chemotherapy remains the treatment modality of choice but has been considered to be immunosuppressive. However, accumulating evidence indicates that many modalities of conventional chemotherapy not only are less immunosuppressive than previously thought but in fact can exert favorable effects on the tumor micro-environment by interfering with suppressive immune cells and by stimulating the release of immune activating molecules by tumor cells. Thus chemotherapy may enhance tumor-specific immunity and synergize with cancer immunotherapy. Addition of pegylated interferon alpha (IFNα) two-b (IIb) to vaccination might even further improve the immune response. This multicenter, open label, non-randomized Phase I/II study will be performed to assess the safety and tolerability of the ISA101/ISA101b vaccine, and the immune modulating effects of ISA101 (with or without pegylated IFNα)/ISA101b when combined with carboplatin and paclitaxel, with or without bevacizumab.


Recruitment information / eligibility

Status Completed
Enrollment 93
Est. completion date August 2018
Est. primary completion date August 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Women = 18 years of age.

2. Cervical cancer confirmed by histology.

3. Advanced or metastatic or recurrent cervical cancer confirmed by clinical and/or radiological proof with no curative treatment options.

4. For cohort 10 (and 12), i.e. patients eligible to receive bevacizumab at each site per standard of care, patients may be primary stage IVB (including persistent) or first recurrent carcinoma of the uterine cervix (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma). Prior treatment with chemotherapy for recurrent disease is not permitted. However, one prior line of chemotherapy with platinum during primary radio-chemotherapy or platinum-base chemotherapy as neoadjuvant chemotherapy prior to surgery is permitted

5. Tumour must be HPV16 positive.

6. Patients should be eligible for chemotherapy with carboplatin and paclitaxel, and have consented with chemotherapy with carboplatin and paclitaxel, before the start of the informed consent procedure for the study.

7. Performance status (WHO scale/ECOG) 1.

8. Written informed consent according to local guidelines.

9. Written approval by the treating physician/investigator of his/her clinical judgment that the patient has a reasonable life expectancy and is sufficiently fit and motivated to complete the study treatment and comply to all study procedures conform the protocol.

Exclusion Criteria:

Treatment:

1. Prior treatment with anti-HPV agents.

2. Chronic systemic steroid use. Local application (i.e. stable doses of topical or inhaled corticosteroids) is allowed.

3. Less than 4 weeks since the last treatment with other cancer therapies, (i.e. endocrine therapy, immunotherapy, radiotherapy, chemotherapy, etc), less than 8 weeks for cranial radiotherapy, and less than 6 weeks for nitrosoureas and mitomycin C.

4. Toxicities resulting from previous anti-cancer therapy must be resolved to = grade 2.

5. Recent treatment (within 30 days of first study treatment) with another investigational drug.

6. Patients with known hypersensitivity to any component of the Investigational Medicinal Product.

7. Any contraindication to the use of authorized applied products (i.e. paclitaxel, carboplatin or bevacizumab).

Haematology and biochemistry:

8. Inadequate bone marrow function: Absolute Neutrophil Count (ANC) < 1.5 x 109/L, or platelet count < 100 x 109/L or hemoglobin < 6 mmol/L.

9. Inadequate liver function, defined as:

- Serum (total) bilirubin > 2 x upper normal limit (ULN);

- Aspartate Aminotransferase (ASAT) or Alanine Aminotransferase (ALAT) > 2.5 x ULN (> 5 x ULN in patients with liver metastases);

- Alkaline phosphatase levels > 2.5 x ULN (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases).

Other:

10. Clinical suspicion or radiological evidence of brain or leptomeningeal metastases.

11. Previous or current malignancies at other sites, with the exception of basal or squamous cell carcinoma of the skin and with the exception of other malignancies from which the patient may be considered cured as evidenced by complete regression of all lesions >10 years ago.

12. Active HIV, chronic hepatitis B or C infection.

13. Patients of childbearing potential not willing to consistently and correctly us a contraceptive method according to ICH (M3) resulting in low failure rate, i.e. less that 1% per year such as oral contraceptives or use of effective means of contraception.

14. Pregnancy or lactation. Serum pregnancy test to be performed within 7 days prior to study treatment start in patients of childbearing potential.

15. Major surgical procedure within 28 days prior to the first study treatment.

16. Uncontrolled sustained hypertension (systolic > 180 mm Hg and/or diastolic > 110mm Hg).

17. Clinically significant (i.e. active) cardiovascular disease defined as:

- Stroke within = 6 months prior to day 1;

- Transient Ischemic Attack (TIA) within = 6 months prior to day 1;

- Myocardial infarction within = 6 months prior to day 1;

- Unstable angina;

- New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure (CHF);

- Serious cardiac arrhythmia requiring medication;

18. History of severe bronchial asthma and/or severe allergy.

19. Evidence of any other medical conditions that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ISA101/ISA101b
Four dose levels ISA101/ISA101b

Locations

Country Name City State
Belgium UZA Antwerp
Belgium Chirec Cancer Institute Brussels
Belgium UZG Gent
Belgium UZL Leuven
Belgium CHU of Liege Site Citadelle Liege
Germany Universitätsklinikum Düsseldorf - Frauenklinik Düsseldorf
Germany Universitätsklinikum Essen - Klinik für Frauenheilkunde Essen
Germany Medizinische Hochschule Hannover - Klinik für Frauenheilkunde Hannover
Germany Universitätsklinikum Heidelberg Heidelberg
Netherlands AMC Amsterdam
Netherlands NKI/AVL Amsterdam
Netherlands UMCG Groningen
Netherlands LUMC Leiden
Netherlands MUMC Maastricht
Netherlands Radboud UMC Nijmegen

Sponsors (2)

Lead Sponsor Collaborator
ISA Pharmaceuticals Dutch Cancer Society

Countries where clinical trial is conducted

Belgium,  Germany,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluate the general responsiveness of the immune system as measured by explorative assays. General responsiveness of the immune system as measured by explorative assays in particular:
Lymphocyte proliferation
Antigen Presenting Cell (APC) function tests
Assay of myeloid and lymphoid cell composition
Recall proliferative responses of Peripheral Blood Mononuclear Cells(PBMCs) in response to common microbial antigens
4 months
Primary HPV-specific immune responses HPV-specific immune responses to different doses of the ISA101 vaccine with or without pegylated interferon alpha (INFa) as combination therapy with carboplatin and paclitaxel will be determined. The HPV-specific immune responses to ISA101b will be qualitatively compared to the responses at the same dose level(s) of ISA101. 4 months
Secondary Evaluate the clinical efficacy by antitumor efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 one year
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A